Dear Editor,
We read with great interest the article by Bucci et al., which investigated the Fibrosis-4 (FIB-4) Index and mortality in COVID‑19 patients admitted to the emergency department [1].
We want to congratulate to authors about this originally. However, we consider that there are some key aspects that need to take into account for proper clinical extrapolation.
First, during COVID-19 pandemic, prediction factors are needed to help front-line providers to identify who might be at higher risk of mortality for respiratory failure needing intensive care admission and ventilator support. Several complex models have been developed to predict these outcomes using clinical data and markers of increased systemic inflammation associated with infection [2]. Recent studies show that the FIB-4 Index, initially developed to predict advanced fibrosis in those with liver disease, may be affected by other systemic diseases, such as COVID-19 through non-hepatic mechanisms, including systemic inflammation and/or bone marrow suppression [3]. Before this study, Sterling et al. demonstrated that FIB-4 is associated with the need for mechanical ventilation and 30-day mortality in patients admitted with COVID-19 [3]. Li et al. demonstrated that FIB-4 is associated with mortality in COVID-19, independent of underlying conditions including liver diseases [4]. In these aspects, we consider that following these published studies the single factor componing FIB-4 score was not predictive of mortality or need for ICU admission, so it is very important to understand how the composite index work so well.
Second, age is a very important factor, because it is in the numerator of the FIB-4 formula and the authors reported a statistically significant difference (p < 0.001) in the age in the group of patients with a FIB-4 > 3.25 for the group with a FIB-4 < 3.25 with a mean age of 76 (70–81) and 57 (51–64), respectively [1].
The missing link is to understand how lung commission in terms of inflamed lung tissue, COVID-related ARDS and extension of lung involvement can be correlated with this index. Also, time to respiratory failure development is another important missing key factor that is interesting to know.
Finally, FIB-4 is an index developed to predict liver fibrosis so it is very interesting to study if this index can predict long-COVID and in particular lung fibrosis development [5].
Further clinical trials need to confirm these observations about the power of FIB-4 as an index and mortality.
Acknowledgements
None.
Declarations
Conflict of interest
Paolo Ruggeri and Antonio Esquinas have no conflicts of interest relating to this manuscript. They disclose financial or non-financial interests that are directly or indirectly related to this manuscript.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Bucci T, Galardo G, Gandini O, Vicario T, Paganelli C, Cerretti S, et al. Fibrosis-4 (FIB-4) index and mortality in COVID-19 patients admitted to the emergency department. Intern Emerg Med. 2022 doi: 10.1007/s11739-022-02997-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2021;31(1):1–10. doi: 10.1002/rmv.2146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sterling RK, Oakes T, Gal TS, Stevens MP, deWit M, Sanyal AJ. The fibrosis-4 index is associated with need for mechanical ventilation and 30-day mortality in patients admitted with coronavirus disease 2019. J Infect Dis. 2020;222(11):1794–1797. doi: 10.1093/infdis/jiaa550. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Li Y, Regan J, Fajnzylber J, Coxen K, Corry H, Wong C, et al. Liver Fibrosis index FIB-4 is associated with mortality in COVID-19. Hepatol Commun. 2021;5(3):434–445. doi: 10.1002/hep4.1650. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. 2020;2020:6175964. doi: 10.1155/2020/6175964. [DOI] [PMC free article] [PubMed] [Google Scholar]